Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Zilurgisertib

Generic Name: Zilurgisertib

Drug Type: Small Molecule

Chemical Formula: C_₃₀H_₃₈N_₄O_₃

CAS Number: 2173389-57-4

Unique Ingredient Identifier: L5Z9S25HO2

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

Phase 1

Completed

Posted: 2021/10/29

Sponsor:Incyte Corporation

ID:NCT05099445

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

Phase 2

Recruiting

Posted: 2021/10/25

Sponsor:Incyte Corporation

ID:NCT05090891

To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma

Phase 1

Completed

Posted: 2020/10/09

Sponsor:Incyte Corporation

ID:NCT04582539

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

Phase 1

Active, not recruiting

Posted: 2020/07/02

Sponsor:Incyte Corporation

ID:NCT04455841

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Incyte and iTeos Terminate Development of Zilurgisertib and Inupadenant Following Disappointing Trial Data

6 months ago

Incyte has halted the development of zilurgisertib, an ALK2 inhibitor, due to limited efficacy observed in a Phase I trial for myelofibrosis-associated anemia and fibrodysplasia ossificans progressiva.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy